These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 15083199

  • 21. Reaction kinetics of cisplatin and its monoaquated species with the modulating agents (di)mesna and thiosulphate.
    Leeuwenkamp OR, Neijt JP, van der Vijgh WJ, Pinedo HM.
    Eur J Cancer; 1991; 27(10):1243-7. PubMed ID: 1835593
    [Abstract] [Full Text] [Related]

  • 22. Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion.
    Smith PF, Booker BM, Creaven P, Perez R, Pendyala L.
    J Clin Pharmacol; 2003 Dec; 43(12):1324-8. PubMed ID: 14615468
    [Abstract] [Full Text] [Related]

  • 23. Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects.
    Goren MP, Houle JM, Bush DA, Li JT, Newman CE, Brade WP.
    Clin Cancer Res; 1998 Oct; 4(10):2313-20. PubMed ID: 9796960
    [Abstract] [Full Text] [Related]

  • 24. Protective effects of MESNA (2-mercaptoethane sulphonate) against acetaminophen-induced hepatorenal oxidative damage in mice.
    Sener G, Sehirli O, Cetinel S, Yeğen BG, Gedik N, Ayanoğlu-Dülger G.
    J Appl Toxicol; 2005 Oct; 25(1):20-9. PubMed ID: 15669031
    [Abstract] [Full Text] [Related]

  • 25. 2-Mercaptoethane sulfonate (MESNA) protects against burn-induced renal injury in rats.
    Sener G, Sehirli O, Erkanli G, Cetinel S, Gedik N, Yeğen B.
    Burns; 2004 Sep; 30(6):557-64. PubMed ID: 15302421
    [Abstract] [Full Text] [Related]

  • 26. In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna.
    Cutler MJ, Urquhart BL, Velenosi TJ, Meyer Zu Schwabedissen HE, Dresser GK, Leake BF, Tirona RG, Kim RB, Freeman DJ.
    J Clin Pharmacol; 2012 Apr; 52(4):530-42. PubMed ID: 21505084
    [Abstract] [Full Text] [Related]

  • 27. Reaction kinetics of cisplatin and its monoaquated species with the (potential) renal protecting agents (di)mesna and thiosulfate. Estimation of the effect of protecting agents on the plasma and peritoneal AUCs of CDDP.
    Leeuwenkamp OR, van der Vijgh WJ, Neijt JP, Pinedo HM.
    Cancer Chemother Pharmacol; 1990 Apr; 27(2):111-4. PubMed ID: 2174306
    [Abstract] [Full Text] [Related]

  • 28. Pharmacokinetics of mesna and dimesna after simultaneous intravenous bolus and infusion administration in patients undergoing bone marrow transplantation.
    el-Yazigi A, Ernst P, al-Rawithi S, Legayada E, Raines DA.
    J Clin Pharmacol; 1997 Jul; 37(7):618-24. PubMed ID: 9243355
    [Abstract] [Full Text] [Related]

  • 29. The Neuroprotective Effect of Mesna on Cisplatin-Induced Neurotoxicity: Behavioral, Electrophysiological, and Molecular Studies.
    Saadati H, Noroozzadeh S, Esmaeili H, Amirshahrokhi K, Shadman J, Niapour A.
    Neurotox Res; 2021 Jun; 39(3):826-840. PubMed ID: 33216283
    [Abstract] [Full Text] [Related]

  • 30. Protection against cisplatin-induced ovarian damage by the antioxidant sodium 2-mercaptoethanesulfonate (mesna) in female rats.
    Yeh J, Kim BS, Peresie J.
    Am J Obstet Gynecol; 2008 Apr; 198(4):463.e1-6; discussion 463.e6-7. PubMed ID: 18395042
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
    Hanada K, Asano K, Nishimura T, Chimata T, Matsuo Y, Tsuchiya M, Ogata H.
    J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
    [Abstract] [Full Text] [Related]

  • 33. Pharmacokinetics and toxicodynamics of cisplatin and its metabolites in rats: relationship between renal handling and nephrotoxicity of cisplatin.
    Hanada K, Ninomiya K, Ogata H.
    J Pharm Pharmacol; 2000 Nov; 52(11):1345-53. PubMed ID: 11186242
    [Abstract] [Full Text] [Related]

  • 34. Two schedules of application for mesna and their influence on the thiol-metabolism.
    Kempgens B, Kisro J, Gruber Y, Bahrs H, Wagner T.
    Int J Clin Pharmacol Ther; 2003 Dec; 41(12):608-9. PubMed ID: 14692714
    [No Abstract] [Full Text] [Related]

  • 35. Novel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787.
    Parker AR, Petluru PN, Nienaber VL, Zhao M, Ayala PY, Badger J, Chie-Leon B, Sridhar V, Logan C, Kochat H, Hausheer FH.
    Onco Targets Ther; 2015 Dec; 8():375-83. PubMed ID: 25678804
    [Abstract] [Full Text] [Related]

  • 36. Mesna inactivates platinum agents in vitro.
    Wolff JE, Egeler RM, Anderson R, Ujack E, Iceton S, Coppes MJ.
    Anticancer Res; 1998 Dec; 18(6A):4077-81. PubMed ID: 9891448
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Chemoprotectants for cancer chemotherapy.
    Dorr RT.
    Semin Oncol; 1991 Feb; 18(1 Suppl 2):48-58. PubMed ID: 1899489
    [Abstract] [Full Text] [Related]

  • 39. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.
    Links M, Lewis C.
    Drugs; 1999 Mar; 57(3):293-308. PubMed ID: 10193684
    [Abstract] [Full Text] [Related]

  • 40. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients.
    Erdlenbruch B, Nier M, Kern W, Hiddemann W, Pekrun A, Lakomek M.
    Eur J Clin Pharmacol; 2001 Aug; 57(5):393-402. PubMed ID: 11599657
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.